193 related articles for article (PubMed ID: 30224718)
1. Idelalisib promotes Bim-dependent apoptosis through AKT/FoxO3a in hepatocellular carcinoma.
Yue D; Sun X
Cell Death Dis; 2018 Sep; 9(10):935. PubMed ID: 30224718
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization.
Fei M; Lu M; Wang Y; Zhao Y; He S; Gao S; Ke Q; Liu Y; Li P; Cui X; Shen A; Cheng C
Med Oncol; 2009; 26(2):178-85. PubMed ID: 18937079
[TBL] [Abstract][Full Text] [Related]
3. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
4. MiRNA-124-3p.1 sensitizes hepatocellular carcinoma cells to sorafenib by regulating FOXO3a by targeting AKT2 and SIRT1.
Dong ZB; Wu HM; He YC; Huang ZT; Weng YH; Li H; Liang C; Yu WM; Chen W
Cell Death Dis; 2022 Jan; 13(1):35. PubMed ID: 35013144
[TBL] [Abstract][Full Text] [Related]
5. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
6. Shikonin induces apoptosis of lung cancer cells via activation of FOXO3a/EGR1/SIRT1 signaling antagonized by p300.
Jeung YJ; Kim HG; Ahn J; Lee HJ; Lee SB; Won M; Jung CR; Im JY; Kim BK; Park SK; Son MJ; Chung KS
Biochim Biophys Acta; 2016 Nov; 1863(11):2584-2593. PubMed ID: 27452907
[TBL] [Abstract][Full Text] [Related]
7. Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells.
Yang LJ; Tang Q; Wu J; Chen Y; Zheng F; Dai Z; Hann SS
J Exp Clin Cancer Res; 2016 Mar; 35():59. PubMed ID: 27036874
[TBL] [Abstract][Full Text] [Related]
8. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
[TBL] [Abstract][Full Text] [Related]
9. FOXO1 and FOXO3a sensitize non-small-cell lung cancer cells to cisplatin-induced apoptosis independent of Bim.
Sun T; Zhang J; Deng B; Fan X; Long T; Jin H; Tao S; Kang P; Tan Q
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(12):1348-1359. PubMed ID: 33167006
[TBL] [Abstract][Full Text] [Related]
10. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
Yang S; Zhu Z; Zhang X; Zhang N; Yao Z
Oncotarget; 2017 Jan; 8(4):6102-6113. PubMed ID: 28008149
[TBL] [Abstract][Full Text] [Related]
11. Alpinia oxyphylla oil induces apoptosis of hepatocellular carcinoma cells via PI3K/Akt pathway in vitro and in vivo.
Hui F; Qin X; Zhang Q; Li R; Liu M; Ren T; Zhao M; Zhao Q
Biomed Pharmacother; 2019 Jan; 109():2365-2374. PubMed ID: 30551496
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
13. Artemisia capillaris extract AC68 induces apoptosis of hepatocellular carcinoma by blocking the PI3K/AKT pathway.
Yan H; Jung KH; Kim J; Rumman M; Oh MS; Hong SS
Biomed Pharmacother; 2018 Feb; 98():134-141. PubMed ID: 29253760
[TBL] [Abstract][Full Text] [Related]
14. PI3Kδ Is a Therapeutic Target in Hepatocellular Carcinoma.
Ko E; Seo HW; Jung ES; Ju S; Kim BH; Cho H; Kim YJ; Park YM; Kim JS; Jung G
Hepatology; 2018 Dec; 68(6):2285-2300. PubMed ID: 30300952
[TBL] [Abstract][Full Text] [Related]
15. Purified vitexin compound 1 induces apoptosis through activation of FOXO3a in hepatocellular carcinoma.
Wang JG; Zheng XX; Zeng GY; Zhou YJ; Yuan H
Oncol Rep; 2014 Jan; 31(1):488-96. PubMed ID: 24247909
[TBL] [Abstract][Full Text] [Related]
16. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
17. Effects of miR-155 on proliferation and apoptosis by regulating FoxO3a/BIM in liver cancer cell line HCCLM3.
Liao WW; Zhang C; Liu FR; Wang WJ
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(5):1277-1285. PubMed ID: 29565484
[TBL] [Abstract][Full Text] [Related]
18. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
19. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
Yan J; Yang S; Tian H; Zhang Y; Zhao H
Cell Death Dis; 2020 Nov; 11(11):943. PubMed ID: 33139695
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA lncARSR Promotes Doxorubicin Resistance in Hepatocellular Carcinoma via Modulating PTEN-PI3K/Akt Pathway.
Li Y; Ye Y; Feng B; Qi Y
J Cell Biochem; 2017 Dec; 118(12):4498-4507. PubMed ID: 28464252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
